Future work should include genetic or pharmacological inhibition of ACVRL1 to determine whether its suppression alone recapitulates the anti-tumor and anti-angiogenic effects of BYJHD, thereby confirming its indispensable role in mediating therapeutic outcomes. The gene discussed is ACVRL1; the disease is neoplasm.